{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:01:25Z","timestamp":1788836485032,"version":"build-2803163510"},"reference-count":22,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To describe a case of levetiracetam-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 31-year-old white male with a low-grade astrocytoma presenting with tonic-clonic seizures was treated with levetiracetam 1 g twice daily and dexamethasone (initial dosage 12 mg\/day, tapered down to 2 mg\/day). On day 45 after levetiracetam initiation, dexamethasone was discontinued and levetiracetam continued. The patient developed fever and dyspnea on day 46 and was admitted to the hospital on day 49. A chest X-ray showed bilateral pulmonary interstitial infiltrates, and laboratory tests showed elevated lactate dehydrogenase (LDH; 288 U\/L [reference range &lt;204]), ferritin (223 ng\/mL [13\u2013178]), and C-reactive protein (CRP; 3.1 mg\/dL [&lt;0.5]). Neurologic fever was suspected and the reinitiation of dexamethasone at 6 mg\/day was followed by improvement of all symptoms; the patient was discharged on day 55 with dexamethasone 4 mg\/day for 2 more days. On day 59, 2 days after the withdrawal of dexamethasone for the second time, the patient presented with a pruritic erythematous maculopapular rash along with recurrence of fever and dyspnea, and was admitted to the hospital. A chest X-ray showed reappearance of the bilateral pulmonary interstitial infiltrates, and laboratory tests showed impaired liver function (alanine aminotransferase 60 U\/L [reference range &lt;56], aspartate aminotransferase 53 U\/L [&lt;30], LDH 516 U\/L, ferritin 419 ng\/mL, and CRP 2.6). A diagnosis of DRESS syndrome was suspected and levetiracetam was discontinued. Upon levetiracetam withdrawal, the patient's symptoms resolved by day 66, and radiological images showed resolution of the interstitial infiltrate by day 68. The patient was discharged on day 68. Low-grade fever persisted until day 71, with no other symptoms. During a 2-month follow-up period, liver function test results returned to normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>DRESS is a hypersensitivity reaction to several drugs, mainly antiepileptic drugs (AEDs), characterized by cutaneous, hematologic, and visceral involvement. Levetiracetam is structurally and pharmacologically unrelated to other AEDs. Previously, only one case of levetiracetam-induced DRESS syndrome had been reported, which required corticosteroids to control symptoms. We describe a case of levetiracetam-induced DRESS syndrome presenting with pneumonitis and hepatitis that resolved with levetiracetam withdrawal. Our patient was classified as a definitive DRESS case according to the RegiSCAR scoring system, which grades DRESS cases. According to the Naranjo probability scale, the adverse drug reaction was considered probable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Although levetiracetam is usually well tolerated, clinicians should be aware of the potential for it to cause DRESS syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1r084","type":"journal-article","created":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T15:46:47Z","timestamp":1341416807000},"page":"e20-e20","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":33,"title":["Levetiracetam-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome"],"prefix":"10.1177","volume":"46","author":[{"given":"Silvia","family":"G\u00f3mez-Zorrilla","sequence":"first","affiliation":[{"name":"Silvia G\u00f3mez-Zorrilla MD, Research Fellow, Infectious Diseases Service, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, University of Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Vallano","family":"Ferraz","sequence":"additional","affiliation":[{"name":"Antonio Vallano Ferraz MD, Staff Member, Clinical Pharmacology Service, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, University of Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Pedr\u00f3s","sequence":"additional","affiliation":[{"name":"Consuelo Pedr\u00f3s MD, Staff Member, Clinical Pharmacology Service, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, University of Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Lemus","sequence":"additional","affiliation":[{"name":"Miguel Lemus MD, Resident, Department of Radiology, Bellvitge University Hospital, University of Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Carmen Pe\u00f1a MD, Clinical Specialist, Infectious Diseases Service, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, University of Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,7,1]]},"reference":[{"key":"bibr1-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03967.x"},{"key":"bibr2-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.01176.x"},{"key":"bibr3-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(01)71754-X"},{"key":"bibr4-aph.1R084","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/10-140"},{"key":"bibr5-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31817-4"},{"key":"bibr6-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P350"},{"key":"bibr7-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.01.017"},{"key":"bibr8-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E042"},{"key":"bibr9-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31663-1"},{"key":"bibr10-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1177\/1756285608094212"},{"key":"bibr11-aph.1R084","first-page":"467","volume":"5","author":"Ulloa CM","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"bibr12-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807302602"},{"key":"bibr13-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07704.x"},{"key":"bibr14-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr15-aph.1R084","first-page":"44631","author":"Real Decreto 1344\/2007, de 11 de octubre, por el que se regula la farmacovigilancia de medicamentos de uso humano","journal-title":"Bolet\u00edn Oficial de Estado 1\/11\/2007"},{"key":"bibr16-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1016\/S1085-5629(96)80038-1"},{"key":"bibr17-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07284.x"},{"key":"bibr18-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07807.x"},{"key":"bibr19-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000334295.50403.4c"},{"key":"bibr20-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000261917.83337.db"},{"key":"bibr21-aph.1R084","first-page":"409","volume":"9","author":"Beswick TC","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"bibr22-aph.1R084","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.4.440"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1R084","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:04Z","timestamp":1777374724000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1R084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":22,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1345\/aph.1R084"],"URL":"https:\/\/doi.org\/10.1345\/aph.1r084","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}